Related Experiment Video
Updated: Aug 5, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Delayed Salvage Radiation Therapy Guided by Contrast-Enhanced Local and Whole-Body Diffusion-Weighted Magnetic
Tadashi Matsumoto1, Shoji Morishita2, Tomohiko Matsuyama1
1Department of Radiation Oncology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Purpose:
Biochemical recurrence (BCR) after radical prostatectomy (RP) is common. Although early prostate-specific-antigen (PSA)-triggered salvage radiation therapy (SRT) improves outcomes, PSA elevation alone cannot reliably distinguish local recurrence from occult metastatic disease, leading to overtreatment. This study retrospectively evaluated long-term outcomes of a PSA-based surveillance strategy, wherein delayed SRT was guided by contrast-enhanced local and whole-body diffusion-weighted magnetic resonance imaging (MRI) and initiated only after radiologic confirmation of macroscopic local recurrence (MLR).
Methods And Materials:
Between January 2015 and June 2023, 226 patients with MRI-detected MLR in the prostate bed were identified during PSA-based surveillance incorporating serial PSA measurements and repeat contrast-enhanced pelvic MRI combined with whole-body diffusion-weighted imaging after RP. SRT was intentionally deferred and initiated only after imaging-confirmed local recurrence with exclusion of distant metastases. Ninety patients who underwent SRT and had ≥6 months of follow-up were included in the final analysis. Radiation therapy was delivered at a total dose of 64 to 68 Gy. The primary endpoint was BCR-free survival. Secondary endpoints included local-recurrence-free survival, distant-metastasis-free survival, overall survival, patterns of failure, and late toxicity.
Results:
The median follow-up was 67 months, and the median PSA level at SRT initiation was 0.98 ng/mL. The estimated 5-year BCR-free survival and local-recurrence-free survival rates were 84.8% and 91.3%, respectively. The 5-year distant metastasis-free survival and overall survival rates were 94.1% and 97.3%, respectively. Disease recurrence occurred in 14 patients (15.6%), predominantly as local recurrence after SRT. Two patients exhibited late grade ≥3 gastrointestinal toxicity. However, no grade ≥3 genitourinary toxicity was reported.
Conclusions:
The PSA-based surveillance strategy, incorporating serial MRI, facilitated the detection of localized recurrence and allowed delayed initiation of SRT in patients with imaging-confirmed MLR following RP. This approach achieved durable disease control with acceptable toxicity in the studied cohort. However, the broader clinical utility of this imaging-based strategy warrants further prospective evaluation.
